Protective Role of Metformin in Glaucoma: Prospective Cohort Study, Meta-Analysis, and Drug-Target Mendelian Randomization - PubMed
7 hours ago
- #Metformin
- #Mendelian Randomization
- #Glaucoma
- Metformin use may protect against glaucoma, as suggested by preclinical studies, but observational studies have shown mixed results.
- A prospective cohort study, meta-analysis, and drug-target Mendelian randomization (MR) analysis were conducted to clarify the association between metformin and glaucoma.
- The cohort study included 24,206 UK Biobank participants with diabetes who were free of glaucoma at baseline.
- Metformin use was associated with a 19% lower glaucoma risk (hazard ratio, 0.81; 95% CI, 0.67-0.97; P = 0.019) in individuals of European ancestry.
- Meta-analysis of cohort studies showed a consistent protective effect of metformin on glaucoma incidence among subjects with diabetes (pooled risk ratio, 0.81; 95% CI, 0.72-0.93; P = 0.002).
- Drug-target MR analysis indicated that genetically proxied effects of metformin targets were associated with a 34% lower glaucoma risk (odds ratio, 0.66; 95% CI, 0.46-0.94; P = 0.022).
- The findings support the need for randomized clinical trials to evaluate metformin's potential as a preventive glaucoma therapy in individuals with diabetes.